Bavarian will market Covid-19 vaccine on its own – but doesn't rule out future partners
In the past, the biotech firm has very publicly stated that partnerships are the way forward regarding its RSV candidate – but when it comes to the firm’s Covid-19 efforts, cards have been kept closer to the chest.
by christian bundgaard, translated by daniel pedersen
There’s no shortage of competition on the Covid-19 vaccine market, and things aren’t made easier for Danish biotech firm Bavarian Nordic by competitors being some of the biggest players in the world – remaining so even after a year and some time since the first vaccines against Covid-19 hit the market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
